WuXi Biologics and Candid Therapeutics Partner on Trispecific T-Cell Engager

• WuXi Biologics has partnered with Candid Therapeutics in a deal worth up to $925 million for the development of a trispecific T-cell Engager.

• The collaboration highlights the capabilities of WuXiBody, WuXi Biologics’ universal multispecific antibody platform.

WuXi Biologics (“WuXi Bio”), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a partnership with Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. Under the agreement, Candid Therapeutics will acquire exclusive global rights to a preclinical trispecific T-cell Engager developed using WuXi Biologics’ WuXiBody platform.

The deal includes an upfront payment and development and sales milestones that could total up to $925 million, along with royalties for WuXi Biologics. This collaboration positions Candid with three T-cell engager (TCE) programs targeting BCMA, CD20, and CD19, enhancing its pipeline for autoimmune and inflammatory disease treatments.

WuXiBody, WuXi Biologics’ proprietary multispecific antibody platform, plays a pivotal role in this partnership. The platform supports the development of trispecific and bispecific antibodies with high expression yield, stability, and solubility, while significantly reducing manufacturing timelines and costs. “This collaboration reinforces WuXi Biologics’ position as a preferred partner for pioneering next-generation modalities,” said Dr. Chris Chen, CEO of WuXi Biologics.

Dr. Ken Song, Chairman, President, and CEO of Candid Therapeutics, expressed enthusiasm for the partnership, stating that the collaboration uniquely positions Candid with advanced capabilities in T-cell engagers for autoimmune disease treatment.

This agreement represents a broader trend in WuXi Biologics’ platform adoption. In 2024, the company enabled seven global discovery programs via its Research (R) platform, with total potential payments exceeding $2.3 billion. WuXi Biologics continues to advance its role as a critical partner in the life sciences sector, fostering the development of transformative therapies for patients worldwide.